JLE

e-VEGF-IMMUNO-actu

MENU

Association bévacizumab – paclitaxel dans le traitement du cancer du sein HER2 négatif en première ligne métastatique : les données de la vraie vie Volume 11, numéro 4, Octobre 2016

  • [1] Cardoso F, Costa A, Norton L. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol. 2014;25:1871-88.
  • [2] Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist. 2004;9 (Suppl. 1):2-10.
  • [3] Miller K, Wang M, Gralow J. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666-76.
  • [4] Miles DW, Chan A, Dirix LY. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28:3239-47.
  • [5] Robert NJ, Dieras V, Glaspy J. RIBBON-1 : randomized, double-blind, placebocontrolled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally récurrent or metastatic breast cancer. J Clin Oncol. 2011;29:1252-60.
  • [6] Rossari JR, Metzger-Filho O, Paesmans M. Bevacizumab and breast cancer : a meta-analysis of first-line phase III studies and a critical reappraisal of available evidence. J Oncol. 2012;2012:417673.
  • [7] Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 2009;101:1642-9.